CA3159749A1 - Salts and forms of an estrogen receptor modulator - Google Patents

Salts and forms of an estrogen receptor modulator

Info

Publication number
CA3159749A1
CA3159749A1 CA3159749A CA3159749A CA3159749A1 CA 3159749 A1 CA3159749 A1 CA 3159749A1 CA 3159749 A CA3159749 A CA 3159749A CA 3159749 A CA3159749 A CA 3159749A CA 3159749 A1 CA3159749 A1 CA 3159749A1
Authority
CA
Canada
Prior art keywords
degrees
compound
pharmaceutically acceptable
peak
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3159749A
Other languages
English (en)
French (fr)
Inventor
Peter Qinhua HUANG
Sayee Gajanan Hegde
Kevin Duane Bunker
John Knight
Deborah Helen Slee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recurium IP Holdings LLC
Original Assignee
Recurium IP Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium IP Holdings LLC filed Critical Recurium IP Holdings LLC
Publication of CA3159749A1 publication Critical patent/CA3159749A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3159749A 2019-11-04 2020-11-02 Salts and forms of an estrogen receptor modulator Pending CA3159749A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930153P 2019-11-04 2019-11-04
US62/930,153 2019-11-04
PCT/US2020/058526 WO2021091819A1 (en) 2019-11-04 2020-11-02 Salts and forms of an estrogen receptor modulator

Publications (1)

Publication Number Publication Date
CA3159749A1 true CA3159749A1 (en) 2021-05-14

Family

ID=75849360

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3159749A Pending CA3159749A1 (en) 2019-11-04 2020-11-02 Salts and forms of an estrogen receptor modulator

Country Status (12)

Country Link
US (1) US20220389006A1 (https=)
EP (1) EP4045507A4 (https=)
JP (1) JP2022553833A (https=)
KR (1) KR20220103977A (https=)
CN (1) CN114945570A (https=)
AU (1) AU2020380211A1 (https=)
BR (1) BR112022008520A2 (https=)
CA (1) CA3159749A1 (https=)
IL (1) IL292680A (https=)
MX (1) MX2022005139A (https=)
TW (1) TW202132294A (https=)
WO (1) WO2021091819A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003440A2 (pt) * 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
CN114929696A (zh) * 2019-05-24 2022-08-19 浙江海正药业股份有限公司 丙烯酸类衍生物的晶型及其制备方法和用途
EP4267578A4 (en) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201028414A (en) * 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
UY35590A (es) * 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
WO2021216671A1 (en) * 2020-04-22 2021-10-28 Recurium Ip Holdings, Llc Preparation of an selective estrogen receptor degrader

Also Published As

Publication number Publication date
TW202132294A (zh) 2021-09-01
EP4045507A4 (en) 2023-11-01
MX2022005139A (es) 2022-06-24
CN114945570A (zh) 2022-08-26
AU2020380211A1 (en) 2022-05-19
US20220389006A1 (en) 2022-12-08
IL292680A (en) 2022-07-01
BR112022008520A2 (pt) 2022-07-26
JP2022553833A (ja) 2022-12-26
WO2021091819A1 (en) 2021-05-14
EP4045507A1 (en) 2022-08-24
KR20220103977A (ko) 2022-07-25

Similar Documents

Publication Publication Date Title
CN102617513B (zh) 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪
AU2021305347A1 (en) Salts and forms of a WEE1 inhibitor
CA3159749A1 (en) Salts and forms of an estrogen receptor modulator
JP2014051517A (ja) デフェラシロックス（ｉｃｌ６７０ａ）の多形形態
CN115135644B (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法及晶型
CN117682950A (zh) 芳（杂）环取代的树豆酮酸a衍生物，药物组合物及其制备方法和应用
JP7266676B2 (ja) チエノピリドン誘導体のカリウム塩一水和物及びその調製方法
JP3194965B2 (ja) 芳香環にフェニル置換基を有するテトラリン、および癲癇、卒中、および脳または脊髄外傷の処置におけるその使用
CA2990747C (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
TW201904954A (zh) 一種苯并哌啶類衍生物的鹽、其晶型及鹽、其晶型的製備方法
TW201815793A (zh) 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法
CN101622257B (zh) N-{2-氟-5-[3-(噻吩-2-羰基)-吡唑并[1,5-a]嘧啶-7-基]-苯基}-N-甲基-乙酰胺的多晶型B
WO2023059610A1 (en) Crystalline forms and processes for the preparation of cannabinoid receptor modulators
WO2023011608A1 (zh) 含三并环类衍生物调节剂、其制备方法和应用
WO2019091046A1 (zh) 一种来那度胺的衍生物的制备方法与应用
TWI267511B (en) Process for preparing 10,11-methanobenzosuberane derivatives
CN116751186B (zh) 一种雌激素受体调节剂的制备及其用途
CN104788372B (zh) 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
CN116082302A (zh) 氘代吲唑-吡啶-苯基-三氟乙基四取代烯烃类化合物及其用途
WO2021228236A1 (zh) 氘代四氢噻吩并[3,4-d]嘧啶二酮化合物以及包含该化合物的药物组合物
WO2014147641A2 (en) Sitagliptin pterostilbene phosphate salt, process for the preparation and pharmaceutical composition thereof
CN116730853A (zh) 新型氨基酮类化合物及其制备方法和用途
WO2020156150A1 (zh) 泊马度胺前体药物盐的多晶型物
CN1938262A (zh) 季铵化合物、其制备方法、脑血管障碍治疗剂及心脏疾病治疗剂
CA2942522A1 (en) 5,5-dioxo-11h-benzo[c][2,1]benzothiazepine derivatives and their use as mu-opioid receptor agonists

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241007

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241007

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241007

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241023

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241023

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250320

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250324

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250324

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250324

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229